ArticlePancreas2026
DNA Hypomethylation in Pancreatic Cancer Tissues Before Treatment, Defined by KRAS -mutated Circulating Tumor DNA, is Associated With Poor Prognosis.
Article in Pancreas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAberrant hypomethylation of long interspersed nucleotide element-1 (LINE-1) and satellite alpha (SATa) in pancreatic cancer cells increases malignant potential. In addition, circulating tumor DNA (ctDNA) is likely to be associated with micrometastasis and appears more frequently in advanced pancreatic ductal adenocarcinoma (PDAC) patients. In this study, we elucidated the relationship between these factors. MATERIALS AND
methodsA total of 37 patients with PDAC who underwent surgery or first-line chemotherapy were selected in 2014-2017. DNA extracted from surgical or biopsy specimens was used to calculate the relative demethylation levels (RDLs) of the LINE-1 and SATa using methylation-specific quantitative PCR. KRAS -mutated ctDNA was monitored using droplet digital PCR. Receiver operating characteristic curve analysis was performed to determine the cut-off values of LINE-1 and SATa RDLs before and after surgery or during first-line chemotherapy based on ctDNA status (presence or absence).
resultsMedian LINE-1 RDL before treatment was higher in patients with ctDNA than in those without, but these cut-off values (LINE-1 ≥0.058 and 0.055) peritreatments did not link to prognosis ( P =0.762 and 0.933). Conversely, the cut-off value of SATa RDL (SATa ≥0.150) based on ctDNA status after treatments showed a significant association with poor prognosis ( P =0.038). On the other hand, the cut-off value of SATa RDL (SATa ≥0.155) before treatment was found to have no association with prognosis ( P =0.408).
conclusionsEvaluating pretreatment tumor DNA hypomethylation together with KRAS -mutated ctDNA status after surgery or initiation of first-line chemotherapy is associated with poor prognosis in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.